Skip to main content

Advertisement

SpringerLink
Log in

In vivo antitumor effects of bitter principles from the antlered form of fruiting bodies of Ganoderma lucidum

  • Original Paper
  • Published:
Journal of Natural Medicines Aims and scope Submit manuscript

Abstract

Two triterpene fractions and a single ganoderma alcohol obtained from an antlered form of the fruiting bodies of Ganoderma lucidum were examined for their antitumor effects on the growth of inoculated mouse Lewis lung carcinoma in mice by intraperitoneal administration. The ganoderma alcohol fraction significantly suppressed the tumor growth at doses of 50 and 100 mg/kg in the treatment period, and even after the administration, showing antitumor activity with a T/C value of 70.6% at a dose of 100 mg/kg. On the other hand, no obvious activity was shown at each dose in the ganoderma-acid-fraction-treated groups. Furthermore, ganoderiol F, which exhibited the strongest cytotoxicity against four tumor cell lines among five ganoderma alcohols examined, remarkably inhibited the tumor growth, accounting for 63.7% and 78.7% of control group at a dose of 5 mg/kg, 54.1% and 63.0% at a dose of 10 mg/kg, and 47.7% and 53.9% at a dose of 20 mg/kg in and after the administration period, respectively, in a dose-dependent manner. These results suggest that the antitumor effects of bitter principles in G. lucidum are mainly due to ganoderma alcohols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Wasser SP, Weis AL (1999) Medicinal properties of substances occurring in higher Basidiomycetes mushrooms: current perspective. Int J Med Mushrooms 1:31–62

    Google Scholar 

  2. Cheung WMW, Hui WS, Chu PWK, Chiu NY (2000) Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett 486:291–296

    Article  PubMed  Google Scholar 

  3. Yang FC, Ke SS, Kuo SS (2000) Effect of fatty acids on the mycelial growth polysaccharide formation by Ganoderma lucidum in shake flask cultures. Enzyme Microb Technol 27:295–301

    Article  PubMed  Google Scholar 

  4. Lin ZB (2001) Pharmacological effects and clinical applications of Ganoderma lucidum. Modern research of Ganoderma lucidum, 2nd edn. Beijing Medical University Press, pp 284–309

  5. Mizuno T, Kawagishi H, Ito H, Shimura K (1988) Immunostimulative antitumor effects of β-d-glucans and chitin substances isolated from some medicinal mushrooms. Bull Fac Agr Shizuoka Univ 38:29–35

    Google Scholar 

  6. Furusawa E, Chou SC, Furusawa S, Hirazami A, Dang Y (1992) Antitumor activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewuis lung carcinoma in synergetic mice. Phytother Res 6:300–304

    Google Scholar 

  7. Zhang L, Zhang M, Zhou Q, Chen J, Zeng F (2000) Solution properties of antitumor sulfated derivatives of α-(1→3)-d-glucan from Ganoderma lucidum. Biosci Biotechnol Biochem 64:1026–1033

    Google Scholar 

  8. Bao XF, Zhen Y, Ruan L, Fang JN (2002) Purification, characterization, and modification of T lymphocyte-stimulating polysaccharide from spores of Ganoderma lucidum. Chem Pharm Bull 50:623–629

    Article  PubMed  Google Scholar 

  9. Gao Y, Zhou S, Jiang W, Huang M, Dai X (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharides extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32:201–215

    Article  PubMed  Google Scholar 

  10. Min BS, Gao JJ, Hattori M (2005) Bitter principles from the fruiting bodies and spores of Ganoderma lucidum. Curr Top Phytochem (in press)

  11. Lin SB, Li CH, Lee SS, Kan LS (2003) Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 72:2381–2390

    Article  PubMed  Google Scholar 

  12. Kimura Y, Taniguchi M, Baba K (2002) Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res 22:3309–3318

    PubMed  Google Scholar 

  13. Min BS, Gao JJ, Nakamura N, Hattori M (2000) Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against Meth-A and LLC tumor cells. Chem Pharm Bull 48:1026–1033

    PubMed  Google Scholar 

  14. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M (2002) New triterpene aldehydes, lucialdehydes A–C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull 50:837–840

    Article  PubMed  Google Scholar 

  15. Gao JJ, Nakamura N, Min BS, Hirakawa A, Zuo F, Hattori M (2004) Quantitative determination of bitter principles in specimens of Ganoderma lucidum using high performance liquid chromatography and its application to the evaluation of ganoderma products. Chem Pharm Bull 52:688–695

    Article  PubMed  Google Scholar 

  16. Arisawa M, Fujita A, Saga M, Fukumura H, Hayashi T, Shimizu M, Morita N (1986) Three new lanostanoids from Ganoderma lucidum. J Nat Prod 49:621–625

    Google Scholar 

  17. Nishitoba T, Oda K, Sato H, Sakamura S (1988) Novel triterpenoids from the fungus Ganoderma lucidum. Agric Biol Chem 52:367–372

    Google Scholar 

  18. Fujita A, Arisawa M, Saga M, Hayashi T, Morita N (1986) Two new lanostanoids from Ganoderma lucidum. J Nat Prod 49:1122–1125

    Google Scholar 

  19. Sato H, Nishitoba T, Shirasu S, Oda K, Sakamura S (1986) Ganoderiol A and B, new triterpenoids from the fungus Ganoderma lucidum (Reishi). Agric Biol Chem 50:2887–2890

    Google Scholar 

  20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112

    PubMed  Google Scholar 

  21. Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, Shoemaker RH (1992) Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52:3029–3034

    PubMed  Google Scholar 

  22. Kato T, Sato K, Kakinuma H, Matsuda Y (1994) Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54:5143–5147

    PubMed  Google Scholar 

  23. Kim HS, Kacew S, Lee BM (1999) In vitro chemopreventive effects of plant polysaccharides (Aloe barbadebsis Miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis 20:1637–1640

    Article  PubMed  Google Scholar 

  24. Min BS, Gao JJ, Lee YH, Nakamura N, Hattori M (2004) Chemical and biological evaluation of germinated and mature antler-shaped fruiting bodies of Ganoderma lucidum. Nat Med 58:91–97

    Google Scholar 

  25. Bao XF, Liu CP, Fang JN, Li XY (2001) Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohydr Res 332:67–74

    Article  PubMed  Google Scholar 

  26. Liu X, Yuan JP, Chung CK, Chen XJ (2002) Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett 182:155–161

    Article  PubMed  Google Scholar 

  27. Kim DH, Shim SB, Kim NJ, Jang IS (1999) β-Glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull 22:162–164

    PubMed  Google Scholar 

  28. Lee SY, Rhee HM (1990) Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull 38:1359–1364

    PubMed  Google Scholar 

  29. Komoda Y, Shimizu M, Sonoda Y, Sato Y (1989) Ganodermic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull 37:531–533

    PubMed  Google Scholar 

  30. Shigeno T (2002) Clinical antlered form Ganoderma lucidum. President Inc. Press, pp 18–19

Download references

Acknowledgements

This paper is a part of the 21st COE program sponsored by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors are grateful to TDK Service Corporation (Tokyo, Japan) and Reishi Sougou Kenkyu Jo (Tokyo, Japan) for providing ganoderma samples and financial support.

Author information

Authors and Affiliations

  1. Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, 930-0194, Japan

    Jiang Jing Gao, Akiko Hirakawa, Byung Sun Min, Norio Nakamura & Masao Hattori

  2. Immunomodulator Laboratory, Korea Research Institute of Bioscience and Biotechnology, Taejon, Korea

    Byung Sun Min

Authors
  1. Jiang Jing Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akiko Hirakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Byung Sun Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norio Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masao Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masao Hattori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, J.J., Hirakawa, A., Min, B.S. et al. In vivo antitumor effects of bitter principles from the antlered form of fruiting bodies of Ganoderma lucidum. J Nat Med 60, 42–48 (2006). https://doi.org/10.1007/s11418-005-0003-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11418-005-0003-5

Keywords

Search

Navigation